Seeking men and women aged 18-65 years whose large B-Cell lymphoma has not responded or come back after treatment for a study of an investigational drug combination.
Participants in this study will be randomly assigned to get either the standard treatment or the investigational drug combined with the standard treatment.
What we're hoping for
We are studying whether adding an investigational drug to the standard treatment for relapsed or refractory diffuse large b-cell lymphoma is better than the standard treatment alone.
ClinicalTrials.gov Identifier: NCT05139017